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rEsEarCh arTiCLE
aBsTraCT
Background and Objective
Inappropriate treatments and drug-drug interactions 
(DDIs) are known to occur in settings where repeat 
prescriptions are issued. In view of this, a study was 
carried out to document any such problematic drug 
prescribing and propose changes that would enhance 
patient safety.
Methods
A random sample of 100 clients who requested 
a repeat prescription at a group of peripheral village 
dispensaries (bere©) in southern Malta was chosen and 
following anonymisation, the drugs requested for such 
prescriptions were entered into a database. A freely 
available online DDI checker was used in the analysis 
of the results and these were rechecked through the 
appropriate section of the British National Formulary. 
The resulting DDIs were then grouped according to type, 
potential effect or disease for which the drugs were used.
results
A total of 255 DDIs were detected in the prescriptions 
of 53 clients. Drug combinations with a potential for 
increased hypotensive effect were the most common 
cause of DDIs (49.8%) in this sample, but other 
categories of DDIs were found. These included DDIs 
which could affect the management of diabetic patients 
(27.3%), patients on psychiatric treatment (7%) and 
anticoagulants (4.8%) as well as DDIs that affected serum 
potassium levels (2.2%).
Conclusions
The results obtained indicate that DDIs are common 
at a number of peripheral village dispensaries in Malta, 
and these could affect disease management in some 
patients. Other DDIs can be potentially harmful. 
Awareness, knowledge and vigilance by the prescribers 
involved remains crucial to address the issues raised 
by DDIs. Suggestions for addressing these issues on an 
administrative level are proposed.
KEYWOrDs: 
Primary Health Care; Drug-drug interactions (DDI); 
Repeat Prescription Clinic; Malta
iNTrODUCTiON
Unmonitored repeat prescriptions are known to have 
adverse, occasional fatal outcomes (Manfredi, Sabbatani, 
Orcioni, Martinelli and Chiodo, 2006). This is an issue 
of concern, particularly since it is known that repeat 
prescribing can occur in settings where patients are not 
regularly reviewed by their general practitioner, thus 
exposing patients to serious adverse effects (Zermansky, 
1996). Some client categories are also known to be at an 
increased risk of pharmacological interactions particularly 
those on polypharmacy, with pluripathology, as well as 
those in the geriatric age group with a deterioration of 
cognitive functions (Castillo, García, Barrios, de Pablos, 
Villar and de la Cuesta, 1995; Shah and Hajjar, 2012). 
Patients with problems to access care are also at an 
increased risk (Farmer, 1995). Use of certain drugs, such 
as warfarin, is another factor which attracts an increase 
risk. Indeed, in a study by Snaith, Pugh, Simpson and 
McLay (2008) on a cohort of patients on warfarin it was 
found that the prescription of interacting medicines was 
common. The prevalent one-off prescriptions in this 
study could have arisen from particular clinical scenarios 
whereby the doctor weighs the benefits and risks of 
combined treatment. Notwithstanding, the common 
occurrence of repeat prescriptions for treatments with a 
potential for drug-drug interactions (DDI) was of concern. 
The possibility that this arises from the dynamics of 
the repeat prescription procedure was considered as an 
important issue in the study by Snaith et al. (2008) and 
this needs to be considered in Malta. 
Regional state health centres, eight in Malta and one 
in Gozo, serve as hubs for the provision of public primary 
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health care in the Maltese Islands. General practitioner 
and nursing services as well as various specialised health 
services, such as immunisation and speech therapy, 
are provided here (Ministry of Health, the Elderly and 
Community Care, 2012). In the villages were no such 
health centres exist, a further service is provided by 
peripheral clinics, locally known as bere©. At these 42 
peripheral clinics basic medical and nursing services 
are provided by appointment (Ministry of Health, the 
Elderly and Community Care, 2012).  Although when 
originally set up in the first half of the nineteenth century 
the peripheral clinics were pioneering gateways for access 
to secondary care (Abela, 2002), these clinics are now 
mostly used to issue repeat prescriptions or medical 
certificates (Sciortino, n/d). For repeat prescriptions, 
the doctor has to rely on the information provided by 
the patient or his/her representative, with no manual 
or electronic records held by the doctor or at the clinic. 
No mechanism is in place such as those used in other 
countries (Floor-Schreudering, de Smet, Buurma, Amini 
and Bouvy, 2011) to monitor and reduce adverse effects 
from DDIs. It was clear that the mechanism for the issuing 
of repeat prescriptions had to be studied as the potential 
for harmful DDIs was clear. The criterion was that no 
harmful DDIs were to be issued in drug prescriptions. 
The present paper gives an overview of the results of the 
first part of the audit cycle carried out to document and 
address DDI issues at these peripheral clinics. 
As patients may personally attend the clinic or 
delegate the request of a repeat prescription to third 
persons, the term ‘client’ is used to refer to persons 
attending the clinic while the ‘patient’ is the person 
needing the prescription irrespective of whether he 
personally attended the clinic or not.
METhOD
Anonymised records were kept of clients asking for 
a repeat prescription from the author at the peripheral 
clinics for the months of June-July 2012. The age and 
gender of the clients as well as the pharmacological name 
and dosage of the medicine requested was recorded. 
A note was also taken of whether the client personally 
attended the clinic or not, and the type of forms presented 
to doctor.
A random sample of 100 clients was chosen from this 
population according to a sampling method provided by 
World Health Organisation (1993) for studies of drug 
use in health facilities. Each client’s list of drugs was 
checked through an online computer programme for 
DDIs (Drug Interactions Checker, 2012) and the resulting 
DDI pairs verified against the Interactions Appendix of 
British National Formulary September issue (2012). The 
resulting DDIs were then grouped according to type, 
potential effect or disease for which the drugs were used.
rEsULTs 
During the two months, a total of 473 clients from 
eight peripheral clinics (i.e. BirΩebbu©a, G˙axaq, Gudja, 
Mqabba, Qrendi, Tarxien, Ûejtun, and Ûurrieq) were 
included in the study. Out of the 100 clients randomly 
selected for study, it turned out that there were equal 
numbers of females (50%) and males (50%). Sixty one 
clients personally attended the clinic, 34 (56%) were 
females while 27 (44%) males. A slightly lower number 
of females, 16 (41%), as compared to 23 (59%) males 
delegated the prescription collection to third persons. 
This random sample of 100 clients had a mean age of 63 
years (median 65 years), the youngest being 14 years and 
the oldest 90 years. Most clients (78%) were between 50 
and 79 years (Table 1). 
AGe 
GROuP 
(yeARs)
0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Number 0 3 1 4 6 19 33 26 7 1
%males 0 66 0 75 33.3 47.4 61 38 43 1
% att. 0 0 0 25 33.3 63 70 77 29 100
% m. att. 0 0 0 33.3 50 42 50 40 0 100
table 1: Age range of clients in the random sample of patients included for study (%males= Number of males in the age 
group expressed as percentage; %att.= Number of patients in the age group who personally attended the clinic expressed as 
percentage; % m. att.= Number of male patients in the age group who personally attended the clinic expressed as percentage)
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NuMBeR 
OF IteMs 
PResCRIBeD 
PeR CLIeNt
NuMBeR 
oF 
CLIeNts
MALe
MALes 
PeRsONALLy 
AtteNDING
CLINIC
% M 
Att.
FeMALes 
FeMALes 
PeRsONALLy 
AtteNDING
CLINIC 
% F 
Att.
% ToT.
Att.
1 17 12 6 50 5 2 40 47.1
2 22 9 5 55.6 13 9 69.2 63.6
3 13 9 4 44.4 4 4 100 61.5
4 6 1 0 0 5 5 100 83.3
5 14 7 6 85.7 7 4 57.1 71.4
6 10 3 0 0 7 4 57.1 40
7 4 3 3 100 1 1 100 100
8 5 1 0 0 4 4 100 80
9 3 3 2 66 0 0 0 66
10 1 0 0 0 1 0 0 0
11 1 1 1 100 0 0 0 100
12 2 0 0 0 2 0 0 0
13 0 0 0 0 0 0 0 0
14 1 0 0 0 1 1 100 100
Table 2: Characterisation of clients according to number of drugs requested (%M att.= Number of males making the request for 
the particular number of items who actually attended the clinic, expressed as percentage; %F att.= Number of females making the 
request for the particular number of items who actually attended the clinic, expressed as percentage; % tot. att.= Total number of 
persons making the request for the particular number of items who actually attended the clinic, expressed as percentage)
A whole array of documentation, averaging around 1.6 
per client, was brought to the doctor for a prescription. 
Eighty five (M=42, F=43) had a yellow Schedule V 
cards and/or the related extension form (DH 29 and DH 
29(ii) respectively). These cards are used by patients to 
obtain free medicines for chronic diseases. A pink form 
(DH128), used by clients with low income or diabetics 
to obtain free medicines was presented by 24 clients 
(M=13, F=11). In the studied population, 21 (M=6, 
F=15) asked for a prescription of at least one controlled 
drug by using a drug control card - DH 680 (i). These 
cards are used to monitor and control the use of narcotic 
and psychotropic drugs as stipulated by Maltese law. 
Together with these documents, 8 (M=4, F=4) 
presented a diabetic permit (SLH 145) necessary for 
the free dispensing of anti-diabetic medicines. Sixteen 
(M=6, F=9) permits necessary to obtain free medicines 
not listed on government formulary were presented, a 
client bringing two permits on behalf of one male patient. 
Although the Maltese Primary Health Care Department 
has issued a memo encouraging the use of a prescription 
green card (PHCD REC/16) to have on record all the 
patient’s medication, only 4 (M=3, F=1) presented this 
card. No patients presented an equivalent form issued 
by Zammit Clapp Hospital, a geriatric rehabilitation 
hospital. Although all the discharge letters from Mater 
Dei Hospital (Malta’s main public hospital) contain the 
list of prescribed drugs for discharged patients, no clients 
brought this document as a reference. On the other hand 
4 (M=3, F=1) used an informal method for making 
their drug request known and this varied from the use 
of a handwritten or typewritten paper containing the list 
of drugs needed, or bringing the medicine boxes to the 
clinic (Table 2).
Polypharmacy was common with an average of 4 items 
per client, varying from one item for 17 clients and one 
client having fourteen items. Clustering tends to occur 
towards a lower number of drugs, with the sample having 
a median of 3 items per person, and 72% of clients having 
5 items or less. 
The drugs or class of drugs with a potential to 
cause DDIs recorded through the study are presented 
in Tables 3 to 9. The heading to each table groups the 
DDIs according to type, potential effect or disease for 
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eNHANCeD HyPOteNsIVe eFFeCt (tOtAL DDIs=113; 49.8%)
Enhanced hypotensive effect when diuretics given with angiotensin-converting-enzyme inhibitors (ACE-inhibitors) (n=20)
Enhanced hypotensive effect when diuretics given with beta-adrenergic-antagonists (beta-blockers) (n=17)
Enhanced hypotensive effect when calcium channel blockers (CCB) given with ACE-inhibitors (n=10) 
Enhanced hypotensive effect when anxiolytics given with ACE-inhibitors (n=9)
Enhanced hypotensive effect when CCBs given with beta-blockers (n=8) 
Enhanced hypotensive effect when CCBs given with diuretics (n=8) 
Enhanced hypotensive effect when anxiolytics given with diuretics (n=8)
Enhanced hypotensive effect when ACE inhibitors given with nitrates (n=7)
Enhanced hypotensive effect when beta-blockers given with ACE-inhibitors (n=5)
Enhances hypotensive effect when anxiolytics given with beta-blockers (n=5)
Enhanced hypotensive effect when beta-blockers given with angiotensin II receptor antagonists  (ARB) (n=4)
Enhanced hypotensive effect when anxiolytics given with nitrates (n=3)
Enhances hypotensive effect when anxiolytics given with ARBs (n=2)
Enhanced hypotensive effect when diuretics given with ARBs (n=1)
Enhanced hypotensive effect when ACE-inhibitors given with levodopa (n=1) 
Enhanced hypotensive effect when anxiolytics given with hydralazine (n=1)
Enhanced hypotensive effect when alpha-blockers given with diuretics (n=1)
Enhanced hypotensive effect when alpha-blockers given with CCBs (n=1)
Enhanced hypotensive effect when alpha-blockers given with beta-blockers(n=1)
Enhanced hypotensive effect when alpha-blockers given with ACE-inhibitors (n=1)
Table 3: DDIs which may cause enhanced hypotensive effect
DRuGs useD IN DIABetIC PAtIeNts (tOtAL OF POteNtIAL DDIs = 62; 27.3%)
Hypoglycaemic effect of metformin possibly enhanced by ACE-inhibitors (n=15)
Warning signs of hypoglycaemia masked by beta-blockers (n=15) 
Hypoglycaemic effect of antidiabetics antagonised by thiazides (n=12)
Loop diuretics antagonise hypoglycaemic effect of antidiabetics (n=7) 
Hypoglycaemic effect of sulphonylureas possibly enhanced by ACE-inhibitors (n=6)
ACE-inhibitors possibly enhance hypoglycaemic effect of insulin (n=4)
Maybe improved glucose tolerance and an additive effect when insulin or sulphonylureas given with fibrates (n=3)
Table 4: DDIs which may interfere with the management of Diabetes Mellitus
which the drugs were used. The total number of relevant 
DDIs is given as ‘total DDIs’ and this is expressed as a 
percentage of all the DDIs found during the study. The 
rest of the table gives a more detailed breakdown of 
the DDIs included under the heading of table, with ‘n’ 
representing the number of relevant DDIs.
DisCUssiON
Drug-drug interactions
Nearly half of the DDIs (49.8%) had the potential 
of causing an enhanced hypotensive effect. Taking into 
account the fact that thiazide-like diuretics have not 
replaced thiazides in the national formulary, 39 DDIs 
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DRuGs useD IN PAtIeNts ON PsyCHIAtRIC tReAtMeNt (tOtAL OF POteNtIAL DDIs = 16; 7%)
Increased sedative effect when tricyclic-related antidepressents (TCA) given with anxioytics (n=7)
Increased sedative effect when anxiolytics and hypnotics given with antipsychotics (n=2)
Increased sedative effect when selective serotonin re-uptake inhibitors antidepressents (SSRIs) given with anxioytics 
(n=1)
Antipsychotics increase plasma concentration of TCAs – possibly increased risk of ventricular arrhythmia (n=1)
Increased risk of bleeding when aspirin given with SSRIs (n=1)
Anticonvulsant effect of anti-epileptics antagonised by TCAs (n=1)
Increased risk of side-effects when clonazepam given with valproate (n=1)
Plasma concentration of quetiapine possibly increased by valproate (n=1)
SSRIs antagonise anticonvulsant effect of antiepileptics (n=1)
Table 5: DDIs which may interfere with the management of patients on psychiatric treatment
eFFeCt ON (ANtI)COAGuLAtION (tOtAL OF POteNtIAL DDIs = 11; 4.8%)
Allopurinol possibly enhances anticoagulant effect of coumarins (n=2)
Anticoagulant effect of coumarins possibly enhanced by omeprazole  (n=2)
Anticoagulant effect of warfarin enhanced by simvastatin (n=2)
Omeprazole reduces antiplatelet action of clopidogrel (n=1)
Increased risk of bleeding when Aspirin given with clopidogrel (n=1)
Anticoagulant effect of coumarins enhanced due to antiplatelet action of clopidogrel; avoidance of coumarins advised by 
manufacturer of clopidogrel (n=1)
Anticoagulant effect of coumarins possibly enhanced by SSRIs (n=1)
Table 6: DDIs which may interfere with coagulation  or the management of patients on anticoagulation
MyOPAtHy (tOtAL OF POteNtIAL DDIs = 9; 4.0%)
Increased risk of myopathy when simvastatin given with amlodipine (n=8)
Increased risk of myopathy when statins given with fibrates (n=1)
Table 7: DDIs which may increase risk of myopthy
eFFeCt ON POtAssIuM BALANCe (tOtAL OF POteNtIAL DDIs = 5; 2.2%)
Increased cardiac toxicity with cardiac glycosides if hypokalaemia occurs with loop diuretics (n=2)
Increased risk of severe hyperkalaemia when ACE-inhibitors given with potassium sparing diuretics (n=2)
Increased risk of hyperkalaemia when ARBs given with aldosterone antagonists (n=1)
table 8: DDIs which may interfere with potassium balance and relevant consequences
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involved drugs which correspond to the first three steps 
proposed by the guidelines of the National Institute 
of Clinical Excellence (NICE) for the management of 
hypertension. Their combination may be interpreted as 
part of an effort to control blood pressure through use of 
multiple drugs (NICE, 2011). 
The number of DDIs with an enhanced hypotensive 
effect increases by a further 34 drug pairs when one 
considers the combination of beta-blockers with these 
drugs. In five clients, it seems that beta-blockers were 
added to diuretics, ACE-inhibitors, angiotensin II receptor 
antagonists (ARBs) and calcium channel blockers (CCBs) 
to achieve a better control of hypertension, with a further 
client also using an alpha-adrenergic-antagonist (alpha-
blockers). For the other DDIs in this category (see Table 
3), a case by case review indicates that their use is mostly 
not in line with the recommendations provided by the 
NICE guidelines. Indeed, while these guidelines suggest 
that beta-blockers should be considered for younger 
people if ACE-inhibitors and ARBs are contraindicated 
or not tolerated, the youngest person to be on beta-
blockers in the study was aged 52 years (NICE 2011, 
p.12). Furthermore, a beta-blocker was added in 8 clients 
without evidence of use of a CCB and in another client 
without the use of an ACE-inhibitors or ARB as suggested 
by NICE (2011, p.13). Contra-indications or intolerance 
to a drug could be behind these cases. One, however, has 
to consider that in Malta, while beta-blockers can be added 
by a general practitioner once the patient is entitled to 
free anti-hypertensive drugs through a Schedule V yellow 
form, a special permit is required to have a CCB added 
on this form. This raises the possibility that doctors may 
be opting for a beta-blocker rather that a CCB to avoid 
lengthier procedures for drug prescriptions. The fact that 
one client only out of the eight using beta-blockers rather 
than CCBs had a permit certainly needs further research 
to be undertaken in this area.
Thirty-six DDIs which could potentially result in 
an enhanced hypotensive effect occurred as part of the 
management of hypertension and another co-morbidity. 
Contrary to the DDIs described above these were probably 
unintentional. DDIs involving use of antihypertensives 
with anxiolytics proved to be the most common (n=25), 
but an enhanced hypotensive effect resulted when 
antihypertensives were used with nitrates (n=10) and 
levodopa (n=1). While short term use of benzodiazepines 
as an anxiolytic is recommended (BNF 2012, p.218), 
a “repeat prescription syndrome” by which patients 
continue taking these drugs long-term is known (Bjerrum 
and Andersen 1996; Neutel, Walop and Patten, 2003). The 
present documentation of enhanced hypotensive effect in 
a country where such long-term use of benzodiazepines 
is known necessitates a review of the prescription of 
anxiolytics and the need to monitor blood pressure at least 
in the patients likely to be effected.
One client had an atenolol and co-amilozide 
combination considered to increase risk of diabetes (NICE 
2011, p.12); the repeat prescription of this once commonly 
used drug combination needs to be addressed.
A quarter of the DDIs were found to potentially affect 
diabetic control (Table 4). ACE-inhibitors are often used in 
diabetic patients (n=25) and together with fibrates (n=3) 
contribute for the attainment of good glycaemic control. 
Nonetheless, DDIs which adversely influence control of 
blood sugar have also been recorded (n=19). Certainly of 
concern are the number of DDIs which can mask warning 
signs of hypoglycaemia (n=15). These cases reveal that in 
patients on anti-diabetic treatment, particularly those with 
relevant DDIs, patients should be educated and glucose 
monitoring carried out more intensely (Hendrychová and 
Vlček, 2012). 
Likewise in patients on psychiatric treatment (Table 5), 
the occurrence of unwanted sedation which arises from 
unwanted DDIs (n=9) should be monitored, particularly 
MIsCeLLANeOus (tOtAL OF POteNtIAL DDIs = 11; 4.8%)
Excretion of aspirin increased by alkaline urine due to some antacids (n=3)
Omeprazole possibly inhibits metabolism of diazepam (increased plasma concentration) (n=2) 
Aspirin antagonises diuretic effect of spirinolactone (n=2)
Thiazides increases cardiac toxicity with amiodarone (n=1)
Plasma concentration of digoxin possibly increased slightly by proton pump inhibitors (n=1)
Increased risk of AV block and bradycardia when cardiac glycosides given with beta-blockers (n=1)
Increased risk of leucopenia and hypersensitivity reactions when allopurinol given with ACE-inhibitors especially with renal 
impairment (n=1)
Table 9: A miscellaneous group of DDIs not classifiable under headings of Table 3 to 8
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in elderly patients taking multiple drugs (Heppner, Christ, 
Gosch, Mühlberg, Bahrmann, Bertsch, Sieber and Singler, 
2012). Increased risk of bleeding (n=1), decreased 
anticonvulsant effects of drugs (n=2) as well as increased 
risk of ventricular arrhythmia (n=1) confirms that special 
care needs to be adopted to prevent DDIs in patients on 
psychiatric treatment (Hahn and Braus, 2012). 
Patients on anticoagulants are another well-known 
risk category for DDIs (Table 6). Allopurinol, omeprazole, 
simvastatin and SSRIs were responsible for a number of 
DDIs with warfarin and coumarins (n=7). Omeprazole is 
well known to reduce the antiplatelet action of clopidogrel 
(n=1) but some studies suggest that this is not important 
(Douglas, Evans, Hingorani, Grosso, Timmis, Hemingway 
and Smeeth, 2012). Likewise even though an increased 
risk of bleeding occurs when low dose aspirin is given with 
clopidogrel (n=1), combination of the two drugs is a well 
known treatment as part of the management of a number 
of cardiac conditions (BNF 2012, p.153).
Nine DDIs exposed patients to an increased risk of 
myopathy (Table 7). Indeed, the prescription of amlodipine 
with simvastatin should be approached with caution as 
this may lead to muscle injury. The United States Food 
and Drug Administration (FDA) recommends that the dose 
of simvastatin should not exceed 20mg when combined 
with a number of drugs, which include amiodarone and 
amlodipine (FDA, 2011). Eight patients were on an 
amlodipine/simvastatin combination in the present study 
but with the dosage of simvastatin being 20mg or less, 
these were not of significance.
Vigilance should be exerted for DDIs which effect serum 
potassium levels (Table 8), particularly in a primary care 
setting were biochemical assessment of serum potassium 
is notoriously problematic (Muscat and Buhagiar, 2011). 
The 5 DDIs which effect potassium levels are likely to be 
significant. Thus, particular attention should be given 
for prescribing drug pairs that increase serum potassium 
levels (Eschmann, Beeler, Kaplan, Schneemann, Zünd and 
Blaser, 2012). 
A further 11 DDIs could not be listed under the 
categories described above (Table 9). Four of these may 
lead to AV block, cardiac toxicity, leucopenia or effect 
digoxin levels which may have adverse outcomes. Such 
combinations need to be avoided.
addressing DDis in Maltese primary 
health Care
This study was undertaken by the author as part of a 
‘Quality Assurance Initiative’ within the Primary Health 
Care Department of Malta (Department of Health, 2012). 
In view of the fact that the data was collected by a single 
person, arguments may be made that this represents a 
limitation as the methodology may have sampled only a 
number of dispensaries from southern Malta and could 
have introduced researcher bias. While these limitations 
may affect the generalisability of the results to other village 
dispensaries in Malta, the results undoubtedly reveal that 
DDIs need to be addressed in repeat prescriptions in 
Maltese public primary health care. 
The results presented above are in line with those 
carried in Primary Health Care settings, such as that 
carried out by Teixeira, Crozatti, Dos Santos and Romano-
Lieber (2012) in Brazil, were the estimated prevalence of 
DDIs was relatively high. In this study by Teixeira et al. 
(2012), clinically significant DDIs occurred in a smaller 
proportion of patients. While this aspect was not studied 
locally, prevention of unwanted or potentially harmful 
DDIs remains a desirable goal for patients both locally 
and abroad. 
The method used in the present study is useful to 
highlight the DDIs prevalent in repeat prescriptions at 
the peripheral clinics, yet it remains too laborious to 
be implemented to address all the DDIs of the clients. 
Computerization of the clinic records and specialised 
programmes to address DDIs have been successfully used 
abroad (Rommers, Teepe-Twiss and Guchelaar, 2011) and 
these can be implemented locally. Nonetheless this will not 
automatically provide a solution for it is known that despite 
the availability and daily use of computerized surveillance 
systems, exposure to potentially relevant DDIs persists. 
Besides being user friendly and simple to manage, such 
programmes also need to be applicable to everyday practice 
(Floor-Schreudering et al., 2011). There will also be the 
need for the prescribing doctors to adopt the tools made 
available to them (Malone and Saverno, 2012).
Community pharmacists are known to have been 
successfully involved in preventing harmful DDIs (Bond, 
Matheson, Williams, Williams and Donnan, 2000). The 
implementation of the Pharmacy Of Your Choice (POYC) 
scheme, places the community pharmacists in a key 
position to deal with problematic issues with DDIs. The 
computerization of patient records adopted in this scheme 
can provide a useful database through which unwanted 
DDIs can be reduced. Abroad, medication review reports 
submitted by pharmacists to the patients’ general 
practitioners is known to have had positive outcomes in 
this regard (Stafford, Stafford, Hughes, Angley, Bereznicki 
and Peterson, 2011).
The dynamics of issuing cards, such as the Schedule 
V, to allow patients with chronic disease to obtain free 
medicines may also be contributing to problems in a local 
scenario. Hospital consultants in different specialties may 
be issuing such cards with little or incomplete knowledge 
of the patient’s medication, exposing patients to DDIs. 
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Reducing the number of such cards may address this 
situation, but access to a national patient medication 
database during the application process for such cards 
remains desirable. Such database will also be useful for 
any doctors in the management of patients. 
Certainly until then, and probably also in such 
situation, it is clear that the role of the general practitioner 
issuing repeat prescriptions in the peripheral clinics 
remains crucial in reducing unwanted DDIs. Any issuing 
of repeat prescriptions should also be documented and 
accompanied by the necessary examinations.
CONCLUsiONs
DDIs are common at a number of peripheral village 
dispensaries in Malta. Some are potentially harmful while 
others may have unwanted outcomes during management 
of chronic diseases. Awareness, knowledge and vigilance 
on behalf of the doctors concerned remains crucial to 
avoid such circumstances. Community pharmacists 
attached to the POYC scheme may also contribute. A 
national database recording patient medication may also 
be implemented and used to further decrease unwanted 
DDIs.
